

CHARACTERISATION OF HUMAN HOLOCARBOXYLASE SYNTHETASE

by

LISA MARIE BAILEY, B.Biotech(Hons)

**A thesis submitted to the University of Adelaide, South
Australia in fulfilment of the requirements for the degree
of
Doctor of Philosophy**



**School of Molecular and Biomedical Science
The University of Adelaide
Adelaide, South Australia, 5005**

December 2008

Abstract

Biotin (also known as vitamin H or vitamin B7) is an essential micronutrient that is utilised by all living organisms. A key enzyme in the lifecycle of biotin is biotin protein ligase (BPL). BPL catalyses the attachment of biotin onto the biotin-requiring enzymes, a family of enzymes that play important roles in essential pathways such as fatty acid synthesis, gluconeogenesis and amino acid metabolism. Whilst there is a catalytic core conserved among the BPLs of all species, the N-terminal region of the molecule varies considerably in length and function. Mammalian BPL, commonly referred to as holocarboxylase synthetase, contains a large N-terminal extension not present in prokaryotes. The function and significance of this N-terminal extension is not understood. The aim of this project was to examine the function of the N-terminal portion of human holocarboxylase synthetase (referred to as HCS).

To date, no crystal structure for HCS has been reported. Insights into the enzyme have come from mutagenesis and proteolytic mapping of eukaryotic BPLs. For example, yeast BPL has a large N-terminal extension analogous to HCS. Previous work in our laboratory has investigated yeast BPL by mapping the domain structure using limited proteolysis. It has been shown that the N-terminus plays a critical role in catalysis as its removal renders the enzyme inactive (Polyak *et al.*, 1999). A similar approach has been applied to map the domain boundaries in HCS. Work by others in our laboratory showed the N-terminal extension of HCS consisted of up to three domains: Met¹-Ala⁸⁰, Ala⁸⁰-Glu¹⁵¹ and Lys¹⁶⁰-Asp³¹¹, joined by two protease sensitive linker regions between Glu¹⁵¹ to Lys¹⁶⁰, and Lys³¹² to Glu³³⁶.

In this study four polyclonal antibodies, raised against peptide epitopes from different regions of HCS, were affinity purified for characterisation. All antibodies detected multiple

isoforms of HCS by Western Blot analysis upon extracts of human embryonic kidney cells. Mass spectrometry determined that these isoforms varied at their N-terminus.

To investigate if the HCS isoforms are subjected to differential localisation into subcellular compartments, three approaches were attempted: immunocytochemistry, overexpression of GFP-tagged HCS and subcellular fractionation followed by Western Blotting. All methods showed all isoforms of HCS localised primarily in the cytosolic fraction, implying that processing of the protein alone is not responsible for determining HCS localisation.

A novel approach to examine potential protein binding partners, based on the work of Choi-Ree *et al.* (2004), using an engineered HCS variant was attempted. Whilst no novel binding partners were identified, studies with this HCS variant revealed intramolecular interactions occurring between the N- and C-terminal portions of the enzyme, which was confirmed by Yeast Two Hybrid Assay.

Multiple Carboxylase Deficiency (MCD) is a disease caused by a defect in biotin metabolism. The more severe neonatal form of the disease is caused by reduced HCS activity, which subsequently affects biotinylation of all the biotin-dependent enzymes.

To examine the critical role of the N-terminus of HCS in biotin metabolism, two fibroblast cell lines isolated from MCD patients who responded poorly to biotin therapy were investigated. Genotyping revealed that the patients were homozygous for the L216R mutation in the N-terminal extension. The patients' fibroblasts had a reduced proliferation rate compared to wildtype cells, and when grown in biotin-deficient media, were less able to respond to the re-addition of biotin. Whilst the HCS mRNA transcript was readily detected in MCD cell lines, protein and enzyme activity could not be detected, implying mutation of this single residue does have drastic effects on protein stability and function. Overexpression studies revealed that wildtype and mutant proteins localise to the same cellular compartments but enzyme activity was severely compromised for HCS-L216R

and could not be elevated by additional biotin. Furthermore, the turn-over rate for the mutant protein was double that of wildtype HCS. These results help to provide a molecular explanation for the incomplete biotin responsiveness of the MCD condition in patients with the HCS-L216R mutation, and imply that this region of the enzyme is critical for HCS function.

Finally, HCS has been implicated in other cellular processes, such as histone modification. Biotinylation is a new class of histone modification which has been reported in the literature. The most common method of analysis of histone biotinylation is the use of streptavidin as a probe, exploiting the strong non-covalent interaction of avidin for biotin. However studies presented in the thesis show that streptavidin should not be used for analysis of histone biotinylation, as it binds to histones independently of biotin. In a biotin-depletion cell culture system, the amount of streptavidin-reactive material in histone extracts, as examined by Western Blotting, was not affected by biotin availability. This was despite the biotin-depletion treatment reducing cell viability and biotinylation of biotin-dependent carboxylases. Blocking biotin binding sites on streptavidin with free biotin prior to Western Blot analysis did not affect histone binding. In contrast, the biotin-containing protein Pyruvate Carboxylase, was not detected by streptavidin that was pre-incubated with biotin. Finally, cells grown in biotin deficient media supplemented with ¹⁴C labelled biotin failed to incorporate biotin onto histone proteins, whereas biotin incorporation onto biotin-dependent carboxylases was readily detected. These results suggest that histone biotinylation may be an artefactual observation, and that streptavidin is not an appropriate tool to measure the dynamics of biotin transfer on and off histone proteins. Analysis with methods which do not rely on secondary detection systems, such as mass spectrometry, will provide the most powerful evidence for histone biotinylation occurring as a physiologically relevant modification.

Statement of Originality

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

Signed

.....

Lisa Marie Bailey

Acknowledgments

My sincerest gratitude goes to my supervisors Prof. John Wallace, Dr Steven Polyak and Dr Grant Booker for their never-ending guidance, encouragement and support.

It's been an honour to work with John, who was always supportive and gave me the freedom to explore and develop ideas. I'm grateful to him for sharing his patience, persistence, extensive knowledge, and occasional glass of red wine with me. I'd like particularly to thank Steven, who gave me my first opportunity, hiring me to work initially as a research assistant in the lab. It was my first taste of the mysterious world of a vitamin until then I'd barely heard of! I'd like to thank you Steven, for encouraging me to continue studying and take up my PhD. Over the subsequent years, no matter how the experiments were going at the time, I always felt so much more enthused and confident after talking things through with you. I'll be forever grateful for that, and none of this work would have been possible without your patience, guidance and friendship.

I'd like to thank Sarawut "Yui" Jitrapakdee for all his helpful comments and reading of manuscripts, and introducing me to the world of Korean BBQ cuisine. I'd also like to thank Prof Murray Whitelaw for advice on manuscripts, and for providing the plasmids and cell lines necessary for the tetracycline-repressible expression studies.

I'm grateful to Dr Callum Wilson, Starship Childrens Hospital, Auckland NZ, for providing MCD fibroblasts and his advice on manuscripts, and to Dr Tim Rayner for encouragement through my honours year and for donating wild-type fibroblasts for use in this study.

I'd also like to thank Dr Roy Gravel and Shannon Healy, at the University Of Calgary, Canada for their assistance with histone extraction and biotin-depletion methods, and for kindly hosting me in their lab for a short time.

Of course it's the people you work with that make life in the lab liveable. Big thanks go out to all the past and present BPL crew. To Nicole Pendini, thanks for letting me use your hard-purified ligases and biotin domains, and for being my BPL buddy. I'll drink a toast (with red champagne of course!) to you finding those crystals! Thanks to Daniel Bird for all his help with the work on the chimera proteins, and for always being there to play with the dry ice when it came in. My thanks to Ruby Ivanov for all her help with work on the L216R mutant, to Lungisa Mayende for continuing the yeast two hybrid work, and to Belinda Ng for continuing the BPL assay development. I'd like to thank past lab members, including Fiona Whelan, Rachel Swift and Lisa Clarke. Particularity for their early work on the domain mapping of HCS and promiscuous biotinylation mutant, that were of great assistance to my project.

Of course that was only half the Wallace lab, and I'd like to thank "the dark side", everyone involved in the IGF work, for making it such a great place to work, and for never ending supplies of cake for morning tea. To Dr Briony Forbes, Kerrie McNeil, Carlie Delaine, Clair Alvino, Dr Kathy Surinya-Johnson, SheeChee Ong, and to past members, Mehrnaz Keyhanfer, Thirajit "O" Boonsaen, Teerakul "Gap" Arpornsuwan, Adam Denley, "Wau" Kuang and to honorary lab members Gemma Brierley, Michelle Zucker, Tamara Cooper, it's been a pleasure. Thanks also to the Booker lab for fun times and particularly to Cvetan Stojkoski for assistance with molecular modelling.

Working in the School of Molecular and Biomedical Sciences has been fantastic, and there are so many people I need to thank. John MacKrill, for assistance with antibody production and showing me the ropes in tissue culture, Serge Volgin in the store, Chris Cursaro for general helping out and of course everyone in CSU! I'd like to thank Velta Vingelis for all her encouragement and sharing her love of teaching with me.

I'm grateful to Dr Meredith Wallwork at Adelaide Microscopy for her expert advice and instruction in microscopy, and of course The Adelaide Proteomics Facility including Prof Peter Hoffman, Dr Chris Bagley, Dr Megan Retallick for mass spectrometry and protein sequencing services.

A big thanks to everyone else I have ever begged, borrowed (but never stole!) things from. You are too numerous to mention, but particularly thanks to Alix Farrell and Dr Edwina Ashby for antibodies I borrowed.

I'd like to acknowledge the Department of Molecular and Biomedical Science, the Faculty of Health Sciences and The Federation of University Women for travel fellowships. I was the recipient of a University of Adelaide Postgraduate Award.

Lastly, I need to thank my friends and family. To all my friends, thanks for keeping me sane. To Kelly, thanks for always being up for coffee and cake at Rumours at the drop of a hat, I wish you all the best in your PhD and whatever comes after that. Thanks for all your support. To Dave, look- I made it! Thanks for all your love and support (and the neck rubs while I was writing this up!) I couldn't have done it without you. Finally, I'd like to dedicate this thesis to my Mum and Dad, for their never-ending love, encouragement and belief in me that made this possible.

Table of Contents

Abstract	i
Statement of Originality	iv
Acknowledgments	v
Table of Contents	viii
List of Figures	xi
List of Tables	xiii
List of publications	xiv
List of Abbreviations	xvii
1 Introduction	20
1.1 Biotin	20
1.2 The biotin cycle	20
1.3 Biotin-dependent enzymes	21
1.4 Biotin domains.....	22
1.5 Biotin protein ligases	25
1.5.1 Reaction mechanism.....	25
1.5.2 Prokaryotic BPLs.....	26
1.5.3 Eukaryotic BPLs	28
1.5.4 Plant BPLs.....	29
1.5.5 Yeast BPLs.....	31
1.5.6 Human HCS	32
1.5.7 Human HCS structure	34
1.6 Biotin in human health.....	36
1.7 Multiple carboxylase deficiency (MCD)	38
1.8 A new role for biotin?.....	42
2 General materials and methods	46
2.1 Materials.....	46
2.1.1 General materials.....	46
2.1.2 Chemical reagents	46
2.1.3 Restriction endonucleases	47
2.1.4 Antibodies.....	47
2.1.5 Bacterial strains.....	48
2.1.6 Bacterial media.....	48
2.1.7 Tissue culture cell lines	48
2.1.8 Tissue culture media	49
2.1.9 Primers	49
2.1.10 Commercial kits.....	51
2.1.11 Buffers and solutions.....	51
2.1.12 Plasmids and vectors	53
2.1.13 Computer software	54
2.1.14 Web resources	54
2.2 General methods.....	54
2.2.1 Culture of mammalian cells	54
2.2.2 Protein techniques.....	56
2.2.3 Immunoprecipitation	58
2.2.4 HCS activity assays.....	58
2.2.5 Mass spectrometry	60
2.2.6 Molecular biology techniques	61

2.3	Molecular cloning HCS constructs.....	65
2.3.2	Generation of mammalian HCS expression plasmid.....	65
3	Production and characterisation of polyclonal antibodies to examine HCS isoforms.....	67
3.1	Background	67
3.2	Specific methods.....	70
3.2.1	Production of polyclonal antibodies in rabbits	70
3.2.2	Monitoring of antibody production by ELISA	70
3.2.3	Antibody purification	71
3.2.4	Purification of HCS isoforms by affinity chromatography	71
3.3	Results	73
3.3.1	Peptide design for immunisation	73
3.3.2	Analysis of antibody production by ELISA.....	73
3.3.3	Affinity purification of antibodies.....	74
3.3.4	Characterisation of HCS with affinity purified antibodies.....	75
3.3.5	Mass spectrometry identification of HCS isoforms.....	77
3.3.6	Cross-reactivity of CHCS antibody.....	83
3.3.7	Immunoprecipitation.....	85
3.3.8	Effect of antibodies on enzyme activity	86
3.4	Discussion	88
4	Subcellular localisation of HCS	95
4.1	Introduction.....	95
4.2	Methods.....	99
4.2.1	Transient transfection of GFP constructs	99
4.2.2	Immunofluorescence	99
4.2.3	Subcellular fractionation	100
4.3	Results for examining subcellular distribution of HCS.....	101
4.3.1	Localisation : a bioinformatic approach	101
4.3.2	GFP labelled HCS localises to the cytoplasm	102
4.3.3	Suitability of antibodies for immunocytochemistry: Co-localisation of anti-HCS antibodies with HCS-GFP	106
4.3.4	Localisation of endogenous HCS	111
4.3.5	Subcellular fractionation analysis.....	116
4.3.6	Evaluation of other HCS antibodies	119
4.4	Discussion	124
5	Examination of HCS L216R in multiple carboxylase deficiency.....	130
5.1	Background	130
5.2	Specific methods	138
5.2.1	Genotyping	138
5.2.2	Reverse transcription PCR.....	138
5.2.3	Biotin-deficient cell culture system	139
5.2.4	Cell proliferation assay	139
5.2.5	Effect of L216R on subcellular localisation of HCS	140
5.2.6	Tetracycline regulated expression of HCS	140
5.3	Results	141
5.3.1	Genotyping of patient cells	141
5.3.2	Effect of L216R HCS on cell proliferation.....	142
5.3.3	Analysis of HCS-L216R expression and activity	148
5.3.4	Effect of L216R mutation on protein stability.....	151
5.3.5	Localisation of L216R HCS	156
5.3.6	Effect of L216R mutation on biotinylation of histones	157
5.4	Discussion.....	158
5.4.1	Effect of HCS-L216R on cellular proliferation: examining the non-biotin responsive phenotype of patient cells.....	158

5.4.2	Expression, production, activity and localisation of HCS-L216R.....	160
5.4.3	Reduced stability of HCS-L216R : a possible mechanism for disease severity	163
6	Artefactual detection of biotin on histones with streptavidin.....	166
6.1	Background	166
6.2	Specific materials and methods	167
6.2.1	Histone extraction.....	167
6.2.2	Biotinylation of yPC-104 domain	167
6.3	Results	168
6.3.1	Biotinylation of carboxylases was sensitive to biotin availability but biotinylation of histones was not.	168
6.3.2	Streptavidin interacts with histones independent of the biotin binding site of the streptavidin.....	170
6.3.3	¹⁴ C biotin fails to be incorporated onto histone proteins but is incorporated into carboxylase proteins.	171
6.4	Discussion	173
7	Final Discussion.....	178
7.1	HCS structure	178
7.2	HCS modifications.....	179
7.3	HCS localisation and correlation with biological function	179
7.4	New directions for HCS deficiency-therapeutics	182
	Appendix 1 – Novel protein interactions of HCS	184
	Appendix 2 – Review: Microbial biotin protein ligases aid in understanding holocarboxylase synthetase deficiency	192
	References.....	203

List of Figures

Figure 1-1 The role of biotin-dependent carboxylases in human metabolism.....	22
Figure 1-2 Structural conservation of the biotin-accepting domain.....	23
Figure 1-3 Schematic representation of the relative position of the biotin attachment site in the five mammalian carboxylases.	24
Figure 1-4 Two step reaction mechanism of biotinylation	25
Figure 1-5 Model of the dual functions of BirA.....	27
Figure 1-6 Diagrammatic comparison of BPLs from different classes.	28
Figure 1-7 Conservation of the catalytic core of BPLs through evolution.	30
Figure 1-8 The N-terminus of yeast BPL is critical for enzyme function.	32
Figure 1-9 Schematic of domain configuration of human HCS.....	36
Figure 1-10 Schematic diagram showing location of mutations that give rise to MCD.	40
Figure 3-1 Comparison of HCS potential initiation codons to the Kozak consensus initiation sequence.	68
Figure 3-2 Titration of rabbit sera was determined by ELISA against the immunising peptide.	74
Figure 3-3 Affinity purification of ChBPL antibody.....	75
Figure 3-4 Detection of HCS isoforms in 293T cell lysate.....	76
Figure 3-5 Transient overexpression of HCS in HeLa and 293T cells.....	77
Figure 3-6 Affinity purification of HCS isoforms.	78
Figure 3-7 LC-ESI Mass Spec analysis for each of the isolated HCS isoforms.....	81
Figure 3-8 Expression of HCS from three potential initiation sites.....	82
Figure 3-9 Cross reactivity of CHCS antibody.	84
Figure 3-10 Immunoprecipitation with HCS antibodies in a variety of cell types.....	86
Figure 3-11 Optimisation of 96-well time resolved fluorescence assay for HCS activity. .	87
Figure 3-12 Effect of antibodies on HCS activity.....	88
Figure 4-1 Localisation of GFP tagged HCS in 293T cells.....	104
Figure 4-2 Localisation of the N-terminal domain of HCS is cytoplasmic.	105
Figure 4-3 Validation of secondary antibody.....	108
Figure 4-4 Co-localisation of GFP tagged HCS with HCS antibodies and secondary Cy3 labelled antibody.	109
Figure 4-5 Co-localisation of HCS-GFP with Cy3 labelled N2 antibody.....	110
Figure 4-6 Localisation of endogenous and overexpressed HCS in 293T cells.....	112
Figure 4-7 Localisation of endogenous HCS in HeLa and HepG2 cells.	113
Figure 4-8 Localisation of untagged HCS isoforms in 293T cells.	115
Figure 4-9 Subcellular fractionation of HeLa cells.....	117
Figure 4-10 Subcellular fractionation of 293T cells (A) and 293T cells overexpressing HCS (B).....	118
Figure 4-11 Immunoprecipitation of 200 µg of mammalian cell lysate with 10 µL anti-HCS antibody (Narang <i>et al.</i> , 2004).....	120
Figure 4-12 Immunoprecipitation with Gravel antibody on 293T-HCS cells.....	121
Figure 4-13 Western Blotting with Gravel anti-HCS serum on fractionated HeLa cell lysate.....	121
Figure 4-14 Gravel anti-HCS antibody shows nuclear staining of HeLa cells.....	122
Figure 4-15 Gravel anti-HCS antibody binds to GFP labelled HCS.....	123
Figure 4-16 Alignment of holocarboxylase synthetase from <i>D. melanogaster</i> and <i>H.sapiens</i>	129

Figure 5-1 Crystal structure of BPL from <i>P.horikoshii</i> shown in complex with biotinyl-5'AMP.....	132
Figure 5-2 Alignment of the N-terminus of vertebrate holocarboxylases.	134
Figure 5-3 Family tree showing patients in the present study PM and JW.	137
Figure 5-4 Genotyping to confirm presence of L216R mutation.	141
Figure 5-5 Growth curve of wildtype fibroblasts (HFF) compared to MCD L216R fibroblasts (MCD-PM and MCD-JW).	142
Figure 5-6 Titration of streptavidin Sepharose to optimise biotin-depletion of media. ...	144
Figure 5-7. Effect of biotin depletion on cell proliferation.	146
Figure 5-8 Effect of biotin supplementation on proliferation of HCS-L216R fibroblasts. .	147
Figure 5-9 Analysis of HCS mRNA expression by RT-PCR in wildtype and MCD cell lines.....	148
Figure 5-10 Western blot of full length HCS protein in wildtype and MCD cells.	149
Figure 5-11 Enzymatic analysis of HCS and HCS-L216R.	151
Figure 5-12 HCS stability assayed by cycloheximide study.....	152
Figure 5-13 Tet-Off expression system used for controlled expression of HCS.	153
Figure 5-14 Stability of HCS L216R is reduced compared to wildtype protein.	154
Figure 5-15 Stability the 76 kDa isoform of HCS is reduced compared to the full length 81 kDa isoform.	155
Figure 5-16 HCS L216R and wildtype HCS have a similar cytosolic localisation.	156
Figure 5-17 Biotinylation of histones in wildtype vs HCS-L216R fibroblasts.....	157
Figure 6-1 Biotinylation of carboxylases was sensitive to biotin availability but biotinylation of histones was not in several cell lines.	169
Figure 6-2 Streptavidin interacts with histones independently of the biotin binding site of streptavidin.....	171
Figure 6-3 ¹⁴ C biotin fails to be incorporated onto histone proteins but is incorporated onto carboxylase proteins.	173
Figure A-1 Interaction of the N- and C-terminus of HCS as examined by yeast two hybrid assay.....	185
Figure A-2 Structural basis for BirA-R118G promiscuous biotinylation.....	186
Figure A-3 Schematic of proteins expressed in 293T cells to examine promiscuous biotinylation	188
Figure A-4 Analysis of mutants confirms promiscuous biotinylation by BirA-R118G, but not of HCS-R508G.....	189

List of Tables

Table 1-1 Summary of known mutations and polymorphisms of the HCLS gene adapted from Suzuki <i>et al.</i> , 2005.	41
Table 2-1 Primer sets used to amplify HCS fragments for cloning into pEGFP vectors. ...	65
Table 3-1 The four different peptide epitopes to which polyclonal antibodies to HCS were raised.	73
Table 3-2 Summary of properties of HCS antibodies reported in the literature.	92
Table 4-1 Co-localisation values for HCS antibodies with GFP-HCS fluorescence.	107
Table 5-1 Effect of MCD mutations on HCS activity: Summary review from the literature.	131
Table 5-2 Activity of endogenous HCS in various cell lines.	150
Table 5-3 Half-Life calculation for wildtype and L216R HCS using the Tet-Off expression system.	154
Table 5-4 Half-Life calculation for wildtype and L216R HCS using the Tet-Off expression system.	156

List of publications

Publications

LM Bailey, RA Gravel, JC Wallace & SW Polyak. (2008) Production and characterisation of polyclonal antibodies to examine isoforms of holocarboxylase synthetase. *Manuscript in preparation*.

NR Pardini[†], **L Bailey**[†], GW Booker, MC Wilce, JC Wallace & SW Polyak. (2008) Microbial Biotin Protein Ligases aid in understanding holocarboxylase synthetase deficiency. *BBA Protein and Proteomics*. 1784(7-8):973-82.

[†]Equal first authorship.

L Bailey, RA Ivanov, S Jitrapakdee, CJ Wilson, JC Wallace and SW Polyak.(2008) Reduced half-life of Holocarboxylase Synthetase from patients with severe multiple carboxylase deficiency. *Human Mutation* 29(6):E47-57.

L Bailey, RA Ivanov, JC Wallace, and SW Polyak. (2008) Artifactual detection of biotin on histones by streptavidin. *Analytical Biochemistry* 373(1):71-7.

Ng B, Polyak SW, Bird D, **Bailey L**, Wallace JC, Booker GW. (2008) *Escherichia coli* biotin protein ligase: Characterisation and development of a high throughput assay. *Analytical Biochemistry* 376(1):131-6.

NR Pardini[†], **LM Bailey**[†], GW Booker, MC Wilce, JC Wallace, and SW Polyak, Ph.D. (2008) Biotin Protein Ligase from *Candida albicans*: Expression, purification and development of a novel assay. *Archives of Biochemistry and Biophysics*. 479(2):163-9.

[†]Equal first authorship.

Conference Proceedings

L Bailey, RA Ivanov, SW Polyak and JC Wallace (2007) Artefactual detection of biotin on histones: non specific binding by streptavidin. *Proceedings of Annual Scientific Meeting of Australian Society for Medical Research South Australia 2007*. Oral Presentation.

L Bailey, SW Polyak and JC Wallace (2007) Subcellular Distribution of HCS Isoforms. *Proceedings of the 32nd Lorne Proteins Conference, Poster 276*.

L Bailey, N Pardini, RD Swift, C Wilson, JC Wallace and SW Polyak (2006) The N-terminal Domain of Holocarboxylase Synthetase (HCS) is critical for correct biotin metabolism in human cells. *New Frontiers Of Biotin Biochemistry, A satellite meeting of the 20th IUBMB International Congress of Biochemistry and Molecular Biology and 11th FAOBMB Congress, Kumamoto Prefecture, Japan June 2006*. Oral Presentation.

L Bailey, N Pardini, RD Swift, C Wilson, JC Wallace and SW Polyak (2006) The N-terminal Domain of Holocarboxylase Synthetase (HCS) is critical for correct biotin metabolism in human cells. *Proceedings of Annual Scientific Meeting of Australian Society for Medical Research South Australia 2006* Oral Presentation, Ross Wishart Finalist Session.

L Bailey, SW Polyak, C Wilson and JC Wallace (2006) A cell culture model of Multiple Carboxylase Deficiency: Examining N-terminal mutations of holocarboxylase synthetase. *Proceedings of the 31st Lorne Proteins Conference, Poster 222*.

L Bailey, SW Polyak and JC Wallace (2005) Production of polyclonal antibodies for functional analysis of human biotin protein ligase (holocarboxylase synthetase), *Proceedings of ComBio 2005*, Poster number POS-MON-01.

L Bailey, SW Polyak and JC Wallace (2005) Characterisation of human biotin protein ligase (holocarboxylase synthetase EC 6.3.4.10). *East Coast Protein Meeting June 2005*. Poster number 1.

L Bailey, SW Polyak and JC Wallace (2005) Characterisation of human biotin protein ligase (holocarboxylase synthetase EC 6.3.4.10) *Proceedings of Annual Scientific Meeting of Australian Society for Medical Research South Australia 2005* Poster number 12.

List of Abbreviations

aa	amino acid
Ab	antibody
ACC	acetyl CoA carboxylase
AD	activation domain
Amp	ampicillin
AP	alkaline phosphatase
APS	ammonium persulphate
ATP	adenosine triphosphate
BirA	biotin inducible repressor A
BCA	bicinchoninic acid
BCCP	biotin carboxyl carrier protein
BLAST	basic local alignment search tool
BME	beta-mercaptoethanol
bp	base pair
BPL	biotin protein ligase
BSA	bovine serum albumin
C-	carboxyl-
C α	central carbon atom
cDNA	complementary deoxyribonucleic acid
cGMP	cyclic guanosine monophosphate
cHCS	C-terminal amino acids 315-726 of HCS
C-HCS	C-terminal antibody to holocarboxylase synthetase
DAPI	4',6-diamidino-2-phenylindole
Daxx	Death domain associated protein
DBD	DNA binding domain
DEPC	diethyl pyrocarbonate
DMEM	Dulbecco's modified eagles medium
DMSO	dimethyl sulfoxide
DNA	deoxynucleotide triphosphate
dNTPs	deoxynucleotide triphosphates
DTT	dithiothreitol
<i>E. coli</i>	<i>Escherichia coli</i>
ECL	enhanced chemiluminescence
EDTA	ethylene diamine tetra-acetic acid
EGTA	ethylene glycol-O,O'-bis-[2-amino-ethyl]-N,N,N',N',-tetraacetic acid
ELISA	enzyme linked immunosorbent assay
Eu	europium
FCS	fetal calf serum
G418	geneticin

GFP	green fluorescent protein
hr	hour
HCS	human holocarboxylase synthetase
HEPES	4-(2-hydroxyethyl)-1-piperazine-ethanesulphonic acid
3-HIA	3-hydroxyisovaleric acid
hPC107	107 amino acids encoding the biotin domain of human pyruvate carboxylase
HRP	horseradish peroxidase
IP	immunoprecipitation
K_a	affinity constant
K_M	Michaelis constant
kb	kilobase pair
kDa	kilodalton
LB	Luria broth
LC-ESI-MS	Liquid chromatography electrospray ionisation tandem mass spectrometry
LplA	lipoyl ligase
m	metre
M	molar
μ	micron
mA	milliampere
MAb	monoclonal antibody
Min	minute, minutes
MCC	methylcrotonyl-CoA carboxylase
MCD	multiple carboxylase deficiency
MOPS	3-morpholinopropanesulfonic acid
MS	mass spectrometry
MW	molecular weight
MWCO	molecular weight cut-off
n	nano
N-	amino-
N1	n-terminal antibody 1 to holocarboxylase synthetase
N2	n-terminal antibody 2 to holocarboxylase synthetase
N3	n-terminal antibody 3 to holocarboxylase synthetase
nHCS	N-terminal amino acids 1-314 of holocarboxylase synthetase
NHS-	N-succinimidyl ester
NLS	nuclear localisation sequence
NMR	nuclear magnetic resonance
$OD_{x\text{ nm}}$	optical density at x nm wavelength
p	pico
PAb	polyclonal antibody
PCC	propionyl-CoA carboxylase
PBS	phosphate buffered saline
PBS-T	phosphate buffered saline and 0.1% (v/v) Tween-20

PBMC	peripheral blood mononuclear cells
PC	pyruvate carboxylase
PCR	polymerase chain reaction
PDB	protein data bank
PFA	paraformaldehyde
PhBPL	<i>P.horikoshii</i> BPL
PKG	protein kinase G
PMSF	phenylmethylsulfonylfluoride
PVDF	polyvinyl difluoride
RNA	ribonucleic acid
RNase	ribonuclease
rpm	revolutions per minute
RT	room temperature
SDS	sodium dodecyl sulphate
SDS-PAGE	sodium dodecyl sulphate polyacrylamide gel electrophoresis
s	second
SEM	standard error of the mean
TBS	tris buffered saline
TBS-T	tris buffered saline and 0.1% (v/v) Tween-20
TEMED	N,N,N,N'-tetramethylethylene-diamine
Tris	2-amino-2-hydroxymethylpropane-1,3-diol
Tween-20	polyoxyethylene-sorbitan monolaurate
U	units (active)
UTR	untranslated region
V_{max}	maximum velocity
UV	ultra violet
WB	Western blot
WT	wild type
yBPL	Yeast (<i>S.cerevisiae</i>) biotin protein ligase
yPC104	104 amino acids encoding the biotin domain of yeast pyruvate carboxylase